sutimlimab   Click here for help

GtoPdb Ligand ID: 9807

Synonyms: BIVV009 | Enjaymo® | IPN-009 | IPN009 | sutimlimab-jome | TNT009
Approved drug Immunopharmacology Ligand
sutimlimab is an approved drug (EMA & FDA (2022))
Compound class: Antibody
Comment: Sutimlimab (TNT009) is a humanised, monoclonal antibody that is designed to selectively inhibit the classical complement pathway by targeting C1s [3]; C1s being the serine protease component of the C1-complex in the complement pathway of the immune system. It prevents hemolysis. Sutimlimab is claimed in True North Therapeutics' patent WO2016164358A1 [4] and is likely to be the antibody designated as VH4/VK2 based on peptides matches between those provided in the submission to the WHO for INN sutimlimab and those in the patent application (namely SEQ IDs NOs 42 and 44). The research code TNT009 was changed to BIVV009 when True North Therapeutics were acquired by Bioverativ (a Sanofi company) in 2017, and clinical trials are ongoing using both of these code names.
Click here for help
Classification Click here for help
Compound class Antibody
Approved drug? Yes (EMA & FDA (2022))
International Nonproprietary Names Click here for help
INN number INN
10737 sutimlimab
Synonyms Click here for help
BIVV009 | Enjaymo® | IPN-009 | IPN009 | sutimlimab-jome | TNT009
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 802
Other databases
GtoPdb PubChem SID 354702279
Search PubMed clinical trials sutimlimab
Search PubMed titles sutimlimab
Search PubMed titles/abstracts sutimlimab